Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target Engagement
Robin R. Frey(AbbVie (United States)), Thomas D. Penning(Abbott Fund), Stephen Valentino(AbbVie (United States)), Jin Wang(AbbVie (United States)), Wei Qiu(Nanfang Hospital), Navendu Jana(AbbVie (United States)), Albert Lai(AbbVie (United States)), Clarissa G. Jakob(AbbVie (United States)), Nicolas J. Kapecki(AbbVie (United States)), Debra C. Ferguson(AbbVie (United States)), F. Gregory Buchanan(AbbVie (United States)), Matthew D. Kurnick(AbbVie (United States)), Kenneth D. Bromberg(AbbVie (United States)), Anura S. Indulkar(AbbVie (United States)), Anup K. Upadhyay(Emory University), Frank Gambino(AbbVie (United States)), Tao Li(AbbVie (United States)), Heath A. Smith(AbbVie (United States)), Ashish Thakur(Agricultural Institute), Michael R. Michaelides(AbbVie (United States)), Yebin Zhou(AbbVie (United States)), Debra Montgomery(AbbVie (United States)), Vlasios Manaves(AbbVie (United States)), Stella Z. Doktor(AbbVie (United States)), Jacob V. Gorman(AbbVie (United States))
Cited by 6
Related Papers
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
|Nature|2017|878
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Prostaglandin E2 Regulates Cell Migration via the Intracellular Activation of the Epidermal Growth Factor Receptor
|Journal of Biological Chemistry|2003|463
Enzymatic and structural insights for substrate specificity of a family of jumonji histone lysine demethylases
|Nature Structural & Molecular Biology|2009|388